Your trusted source for investing success

Tag: insulin

Valeritas Presents Data Showing Greater Reductions in A1c and Insulin Dose with V-Go® Wearable Insulin Delivery Device Compared to Insulin Pen Devices in Patients with Type 2 Diabetes

Valeritas Holdings (OTCQB:VLRX) today announced data showing greater reductions in A1c and insulin dose in patients with type 2 diabetes who used V-Go® Wearable Insulin Delivery device compared to patients using insulin pen devices. The data were presented as an E-Poster at The 10th International Conference on Advanced Technologies &

PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today discussed the comparator arm for its upcoming clinical trial and provided additional clarification on its recent pre-IND meeting with the U.S. Food and Drug

PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, officially announced today that PharmaCyte has retained Facet Life Sciences, Inc. (Facet) to guide PharmaCyte through its pancreatic cancer therapy development lifecycle with the U.S.

Lenis® Receives Next Regulatory Certification

Eternity Healthcare Inc. (OTC:ETAH), announces first regulatory approval of its Loader for the Lenis® Needle-Free Injection system.

“CE Certification opens the door for regulatory approval in the EU as well as other countries that follow the EU.  With the most difficult components already certified, we remain confident the final two certifications

PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be meeting with the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) on

PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that recent research performed at the Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University’s Feinberg School of Medicine and

FDA Clears Integration Between LifeScan’s OneTouch Verio Flex Blood Glucose Monitoring System and WellDoc’s BlueStar Diabetes Management Platform

LifeScan, Inc., part of the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced the U.S. Food and Drug Administration (FDA) has cleared the wireless integration of the OneTouch Verio Flex® blood glucose monitoring system with WellDoc Inc.’s clinically validated diabetes management platform,

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network